ProCE Banner Activity

CME

Advances in Hemophilia A: Expert Guidance and Practical Case Discussions

Multimedia
Watch this interactive, CME-certified video from a live CCO symposium at ASH 2019 where expert faculty review new developments in factor and nonfactor replacement strategies for hemophilia A through case-based examples.

Physicians: Maximum of 3.00 AMA PRA Category 1 Credits

Released: February 04, 2020

Expiration: February 03, 2021

No longer available for credit.

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Stacy E. Croteau

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Cindy A. Leissinger

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hemophilia A.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement individualized hemophilia A management strategies that optimize adherence, outcomes, and utilization of resources
  • Analyze recent data on the efficacy, safety, and tolerability of emerging nonfactor replacement strategies for the management of hemophilia A with and without inhibitors
  • Discuss progress in the management of hemophilia A with factor-based interventions, including use of prolonged half-life agents
  • Develop approaches for individualizing therapy based on patient- and disease-specific characteristics
  • Evaluate available data for novel agents and treatment strategies and determine patients with hemophilia A who may be eligible for a clinical trial.

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bioverativ, Pfizer, Roche/Genentech, and Shire and has ownership interest in Alnylam.

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Stacy E. Croteau, MD, MMS, has disclosed that she has received consulting fees from Bayer, BioMarin, Bioverativ, Catalyst Biosciences, CSL Behring, Genentech, Novo Nordisk, and Octapharma and funds for research support from Boehringer Ingelheim, Genentech, Octapharma, Pfizer, and Spark.

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Cindy A. Leissinger, MD, has disclosed that she has received consulting fees from Bayer, CSL Behring, Kedrion, Genentech/Roche, Spark, Takeda, and UniQure and funds for research support from Genentech/Roche.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received consulting fees for CSL Behring, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Shire/Takeda, Spark, and UniQure; fees for non-CME/CE services from Bioverativ and Genentech; and funds for research support from Genentech.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello, BA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom as no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 3 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 04, 2020, through February 03, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in integrating optimal therapy into the treatment of patients with hemophilia.